BioCentury
ARTICLE | Clinical News

Avanafil: Phase III started

February 16, 2009 8:00 AM UTC

Vivus began the double-blind, U.S., Phase III REVIVIE-Diabetes trial (TA-302) to compare 100 and 200 mg doses of oral avanafil vs. placebo in about 375 men with Type I or Type II diabetes. Last year, ...